CCCC
C4 Therapeutics, Inc.
Price Chart
Latest Quote
$3.71
-0.14 (-3.64%)
Current Price
| Previous Close | $3.85 |
| Open | $3.81 |
| Day High | $3.86 |
| Day Low | $3.69 |
| Volume | 1,856,452 |
Stock Information
| Shares Outstanding | 123.03M |
| Total Debt | $56.86M |
| Cash Equivalents | $253.66M |
| Revenue | $35.04M |
| Net Income | $-101.42M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $456.42M |
| EPS (TTM) | $-0.91 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $259.62M |
| Sales | $35.04M |
| Income | $-101.42M |
| Book/sh | $2.01 |
| Cash/sh | $2.06 |
| Employees | 104 |
Financial Ratios
| Quick Ratio | 5.29 |
| Current Ratio | 5.45 |
| Debt/Eq | 23.00 |
Returns & Margins
| ROA | -19.25% |
| ROE | -48.14% |
| Gross Margin | 86.34% |
| Operating Margin | -397.88% |
| Profit Margin | -289.44% |
Ownership
| Insider Ownership | 0.83% |
| Institutional Ownership | 102.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.72 |
| P/S | 13.03 |
| P/B | 1.84 |
Analyst Data
| Recommendation | none |
| Target Price | $13.33 |
Technical Indicators
| SMA20 | $3.94 |
| SMA50 | $3.95 |
| SMA200 | $3.01 |
| RSI | 52.59 |
| ATR | 0.2739 |
| Shares Float | 94.52M |
| Short Float | 27.84% |
| Short Ratio | 12.57 |
| Volatility | 2.95 |
| Rel Volume | 0.78 |
Performance History
| Week | -7.25% |
| Month | +1.37% |
| Quarter | -15.10% |
| 6 Months | +37.41% |
| YTD | +92.23% |
| Year | +43.80% |
| 3 Years | +12.08% |
| 5 Years | -90.94% |
| 10 Years | -85.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $3.71 | 1,857,200 |
| 2026-08-27 | $4.10 | 1,988,400 |
| 2026-08-26 | $4.24 | 1,861,700 |
| 2026-08-25 | $4.20 | 4,285,800 |
| 2026-08-24 | $4.10 | 1,752,900 |
| 2026-08-21 | $4.00 | 1,160,600 |
| 2026-08-20 | $4.03 | 2,272,700 |
| 2026-08-19 | $4.21 | 2,848,800 |
| 2026-08-18 | $4.18 | 2,878,700 |
| 2026-08-17 | $4.26 | 2,086,800 |
| 2026-08-14 | $4.24 | 3,399,000 |
| 2026-08-13 | $4.08 | 3,726,100 |
| 2026-08-12 | $3.90 | 1,956,800 |
| 2026-08-11 | $3.87 | 3,085,400 |
| 2026-08-10 | $3.62 | 1,963,800 |
| 2026-08-07 | $3.73 | 1,504,100 |
| 2026-08-06 | $3.64 | 1,823,800 |
| 2026-08-05 | $3.62 | 2,556,300 |
| 2026-08-04 | $3.61 | 2,519,600 |
| 2026-08-03 | $3.50 | 2,244,200 |
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Zacks âĸ 2026-08-21T16:00:05Z
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2026-08-11T12:15:02Z
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-07-07T13:40:03Z
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Zacks âĸ 2026-07-03T16:00:03Z
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
Insider Monkey âĸ 2026-07-03T13:11:55Z
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks âĸ 2026-06-18T13:40:04Z
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
MT Newswires âĸ 2026-06-11T11:46:47ZC4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-06-01T16:00:04Z
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-06-01T13:40:03Z
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
Simply Wall St. âĸ 2026-05-15T13:15:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $35,947,000 | $35,584,000 | $20,756,000 | $31,096,000 |
| Operating Revenue | $35,947,000 | $35,584,000 | $20,756,000 | $31,096,000 |
| Expenses | ||||
| Total Expenses | $140,436,000 | $152,761,000 | $159,787,000 | $160,630,000 |
| Other Income Expense | $-10,733,000 | $-2,437,000 | $-621,000 | - |
| Net Non Operating Interest Income Expense | $10,349,000 | $14,429,000 | $8,439,000 | $1,359,000 |
| Operating Expense | $140,436,000 | $152,761,000 | $159,787,000 | $160,630,000 |
| General And Administrative Expense | $36,196,000 | $42,124,000 | $42,081,000 | $42,789,000 |
| Interest Expense | - | $0 | $1,373,000 | $2,216,000 |
| Interest Expense Non Operating | - | $0 | $1,373,000 | $2,216,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Net Interest Income | $10,349,000 | $14,429,000 | $8,439,000 | $1,359,000 |
| Interest Income | $10,349,000 | $14,429,000 | $9,812,000 | $3,575,000 |
| Normalized Income | $-96,514,930 | $-103,390,770 | $-132,002,410 | $-128,175,000 |
| Net Income From Continuing And Discontinued Operation | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Total Operating Income As Reported | $-115,222,000 | $-119,614,000 | $-139,031,000 | $-129,534,000 |
| Net Income Common Stockholders | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Net Income | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Net Income Including Noncontrolling Interests | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Net Income Continuous Operations | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Pretax Income | $-104,873,000 | $-105,185,000 | $-131,213,000 | $-128,175,000 |
| Special Income Charges | $-10,733,000 | $-2,437,000 | $-621,000 | $0 |
| Interest Income Non Operating | $10,349,000 | $14,429,000 | $9,812,000 | $3,575,000 |
| Operating Income | $-104,489,000 | $-117,177,000 | $-139,031,000 | $-129,534,000 |
| Per Share | ||||
| Diluted EPS | $-1.27 | $-1.52 | $-2.67 | $-2.62 |
| Basic EPS | $-1.27 | $-1.52 | $-2.67 | $-2.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,253,930 | $-511,770 | $-130,410 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-91,797,000 | $-112,922,000 | $-127,339,000 | $-124,283,000 |
| Total Unusual Items | $-10,733,000 | $-2,437,000 | $-621,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-10,733,000 | $-2,437,000 | $-621,000 | $0 |
| Reconciled Depreciation | $1,959,000 | $1,818,000 | $1,880,000 | $1,676,000 |
| EBITDA (Bullshit earnings) | $-102,530,000 | $-115,359,000 | $-127,960,000 | $-124,283,000 |
| EBIT | $-104,489,000 | $-117,177,000 | $-129,840,000 | $-125,959,000 |
| Diluted Average Shares | $82,894,459 | $69,372,993 | $49,640,505 | $48,861,665 |
| Basic Average Shares | $82,894,459 | $69,372,993 | $49,640,505 | $48,861,665 |
| Diluted NI Availto Com Stockholders | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Tax Provision | $121,000 | $131,000 | $1,280,000 | $0 |
| Impairment Of Capital Assets | $10,733,000 | - | - | - |
| Restructuring And Mergern Acquisition | $0 | $2,437,000 | $0 | - |
| Research And Development | $104,240,000 | $110,637,000 | $117,706,000 | $117,841,000 |
| Selling General And Administration | $36,196,000 | $42,124,000 | $42,081,000 | $42,789,000 |
| Other Gand A | $10,859,000 | $10,846,000 | $11,837,000 | $12,243,000 |
| Salaries And Wages | $25,337,000 | $31,278,000 | $30,244,000 | $30,546,000 |
| Other Special Charges | - | - | $621,000 | - |
Fetched: 2026-08-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $256,587,000 | $215,986,000 | $246,114,000 | $289,234,000 |
| Total Assets | $359,075,000 | $349,602,000 | $376,451,000 | $430,840,000 |
| Total Non Current Assets | $100,965,000 | $91,835,000 | $105,262,000 | $143,283,000 |
| Other Non Current Assets | $7,126,000 | $6,098,000 | $6,166,000 | $4,805,000 |
| Investmentin Financial Assets | $48,563,000 | $22,359,000 | $28,008,000 | $60,962,000 |
| Current Assets | $258,110,000 | $257,767,000 | $271,189,000 | $287,557,000 |
| Other Current Assets | $7,172,000 | $9,761,000 | $5,709,000 | $9,931,000 |
| Receivables | $2,401,000 | $3,102,000 | $11,799,000 | $1,473,000 |
| Accounts Receivable | $2,401,000 | $3,102,000 | $11,799,000 | $1,473,000 |
| Cash Cash Equivalents And Short Term Investments | $248,537,000 | $244,904,000 | $253,681,000 | $276,153,000 |
| Cash And Cash Equivalents | $74,603,000 | $55,499,000 | $126,590,000 | $29,754,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $59,982,000 | $65,756,000 | $70,976,000 | $87,152,000 |
| Long Term Debt And Capital Lease Obligation | $53,615,000 | $59,982,000 | $65,757,000 | $80,165,000 |
| Current Debt And Capital Lease Obligation | $6,367,000 | $5,774,000 | $5,219,000 | $6,987,000 |
| Long Term Debt | - | - | - | $9,195,000 |
| Current Debt | - | - | - | $2,287,000 |
| Other Current Borrowings | - | - | - | $2,287,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $102,488,000 | $133,616,000 | $130,337,000 | $141,606,000 |
| Total Non Current Liabilities Net Minority Interest | $69,456,000 | $88,439,000 | $87,571,000 | $97,060,000 |
| Non Current Deferred Liabilities | $15,841,000 | $28,457,000 | $21,814,000 | $16,895,000 |
| Current Liabilities | $33,032,000 | $45,177,000 | $42,766,000 | $44,546,000 |
| Other Current Liabilities | $1,399,000 | $1,871,000 | $2,043,000 | $3,114,000 |
| Current Deferred Liabilities | $12,493,000 | $18,712,000 | $15,471,000 | $16,618,000 |
| Payables And Accrued Expenses | $4,117,000 | $11,392,000 | $12,689,000 | $10,996,000 |
| Payables | $858,000 | $1,328,000 | $1,446,000 | $1,172,000 |
| Accounts Payable | $858,000 | $1,328,000 | $1,446,000 | $1,172,000 |
| Equity | ||||
| Common Stock Equity | $256,587,000 | $215,986,000 | $246,114,000 | $289,234,000 |
| Total Equity Gross Minority Interest | $256,587,000 | $215,986,000 | $246,114,000 | $289,234,000 |
| Stockholders Equity | $256,587,000 | $215,986,000 | $246,114,000 | $289,234,000 |
| Gains Losses Not Affecting Retained Earnings | $50,000 | $53,000 | $-127,000 | $-4,137,000 |
| Other Equity Adjustments | $50,000 | $53,000 | $-127,000 | $-4,137,000 |
| Retained Earnings | $-738,693,000 | $-633,699,000 | $-528,383,000 | $-395,890,000 |
| Other | ||||
| Ordinary Shares Number | $96,914,418 | $70,625,899 | $60,467,188 | $48,966,216 |
| Share Issued | $96,914,418 | $70,625,899 | $60,467,188 | $48,966,216 |
| Tangible Book Value | $256,587,000 | $215,986,000 | $246,114,000 | $289,234,000 |
| Invested Capital | $256,587,000 | $215,986,000 | $246,114,000 | $300,716,000 |
| Working Capital | $225,078,000 | $212,590,000 | $228,423,000 | $243,011,000 |
| Capital Lease Obligations | $59,982,000 | $65,756,000 | $70,976,000 | $75,670,000 |
| Total Capitalization | $256,587,000 | $215,986,000 | $246,114,000 | $298,429,000 |
| Additional Paid In Capital | $995,221,000 | $849,625,000 | $774,618,000 | $689,256,000 |
| Capital Stock | $9,000 | $7,000 | $6,000 | $5,000 |
| Common Stock | $9,000 | $7,000 | $6,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $15,841,000 | $28,457,000 | $21,814,000 | $16,895,000 |
| Long Term Capital Lease Obligation | $53,615,000 | $59,982,000 | $65,757,000 | $70,970,000 |
| Current Deferred Revenue | $12,493,000 | $18,712,000 | $15,471,000 | $16,618,000 |
| Current Capital Lease Obligation | $6,367,000 | $5,774,000 | $5,219,000 | $4,700,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $8,656,000 | $7,428,000 | $7,344,000 | $6,831,000 |
| Current Accrued Expenses | $3,259,000 | $10,064,000 | $11,243,000 | $9,824,000 |
| Investments And Advances | $48,563,000 | $22,359,000 | $28,008,000 | $60,962,000 |
| Available For Sale Securities | $48,563,000 | $22,359,000 | $28,008,000 | $60,962,000 |
| Net PPE | $45,276,000 | $63,378,000 | $71,088,000 | $77,516,000 |
| Accumulated Depreciation | $-10,777,000 | $-9,236,000 | $-7,763,000 | $-8,123,000 |
| Gross PPE | $56,053,000 | $72,614,000 | $78,851,000 | $85,639,000 |
| Leases | $4,548,000 | $4,712,000 | $4,712,000 | $4,682,000 |
| Other Properties | $49,351,000 | $65,748,000 | $71,998,000 | $78,873,000 |
| Machinery Furniture Equipment | $2,154,000 | $2,154,000 | $2,141,000 | $1,901,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $173,934,000 | $189,405,000 | $127,091,000 | $246,399,000 |
| Construction In Progress | - | - | $0 | $183,000 |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-08-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-99,301,000 | $-65,337,000 | $-108,546,000 | $-111,435,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-98,694,000 | $-65,157,000 | $-106,838,000 | $-105,939,000 |
| Cash Flow From Continuing Operating Activities | $-98,694,000 | $-65,157,000 | $-106,838,000 | $-105,939,000 |
| Operating Gains Losses | - | - | $621,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-607,000 | $-180,000 | $-1,708,000 | $-5,496,000 |
| Investing Cash Flow | $-8,601,000 | $-51,270,000 | $158,349,000 | $58,422,000 |
| Cash Flow From Continuing Investing Activities | $-8,601,000 | $-51,270,000 | $158,349,000 | $58,422,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-193,000 | $-194,000 | $-110,000 | $0 |
| Issuance Of Capital Stock | $126,211,000 | $44,370,000 | $57,673,000 | $0 |
| Financing Cash Flow | $126,399,000 | $45,336,000 | $45,489,000 | $1,147,000 |
| Cash Flow From Continuing Financing Activities | $126,399,000 | $45,336,000 | $45,489,000 | $1,147,000 |
| Net Other Financing Charges | $274,000 | $382,000 | $368,000 | $370,000 |
| Net Common Stock Issuance | $126,018,000 | $44,176,000 | $57,563,000 | $0 |
| Common Stock Issuance | $126,211,000 | $44,370,000 | $57,673,000 | $0 |
| Other | ||||
| End Cash Position | $78,046,000 | $58,942,000 | $130,033,000 | $33,033,000 |
| Beginning Cash Position | $58,942,000 | $130,033,000 | $33,033,000 | $79,403,000 |
| Changes In Cash | $19,104,000 | $-71,091,000 | $97,000,000 | $-46,370,000 |
| Proceeds From Stock Option Exercised | $107,000 | $778,000 | $58,000 | $777,000 |
| Common Stock Payments | $-193,000 | $-194,000 | $-110,000 | $0 |
| Net Investment Purchase And Sale | $-7,994,000 | $-51,090,000 | $160,057,000 | $63,918,000 |
| Sale Of Investment | $219,080,000 | $233,231,000 | $289,955,000 | $283,445,000 |
| Purchase Of Investment | $-227,074,000 | $-284,321,000 | $-129,898,000 | $-219,527,000 |
| Net PPE Purchase And Sale | $-607,000 | $-180,000 | $-1,708,000 | $-5,496,000 |
| Purchase Of PPE | $-607,000 | $-180,000 | $-1,708,000 | $-5,496,000 |
| Change In Working Capital | $-29,282,000 | $7,648,000 | $-6,938,000 | $-16,779,000 |
| Change In Other Working Capital | $-18,836,000 | $9,884,000 | $3,772,000 | $-22,654,000 |
| Change In Other Current Liabilities | $-5,774,000 | $-5,219,000 | $-4,695,000 | $-507,000 |
| Change In Payables And Accrued Expense | $-6,517,000 | $-1,386,000 | $1,589,000 | $1,750,000 |
| Change In Accrued Expense | $-6,049,000 | $-1,267,000 | $1,316,000 | $5,083,000 |
| Change In Payable | $-468,000 | $-119,000 | $273,000 | $-3,333,000 |
| Change In Account Payable | $-468,000 | $-119,000 | $273,000 | $-3,333,000 |
| Change In Prepaid Assets | $1,144,000 | $-4,328,000 | $2,723,000 | $388,000 |
| Change In Receivables | $701,000 | $8,697,000 | $-10,327,000 | $4,244,000 |
| Changes In Account Receivables | $701,000 | $8,697,000 | $-10,327,000 | $4,244,000 |
| Other Non Cash Items | $99,000 | $6,000 | $482,000 | $713,000 |
| Stock Based Compensation | $19,099,000 | $29,662,000 | $27,235,000 | $30,016,000 |
| Asset Impairment Charge | $17,167,000 | $6,421,000 | $6,159,000 | $5,896,000 |
| Amortization Of Securities | $-2,742,000 | $-5,396,000 | $-3,784,000 | $714,000 |
| Depreciation Amortization Depletion | $1,959,000 | $1,818,000 | $1,880,000 | $1,676,000 |
| Depreciation And Amortization | $1,959,000 | $1,818,000 | $1,880,000 | $1,676,000 |
| Net Income From Continuing Operations | $-104,994,000 | $-105,316,000 | $-132,493,000 | $-128,175,000 |
| Repayment Of Debt | - | $0 | $-12,500,000 | $0 |
| Interest Paid Supplemental Data | - | $0 | $990,000 | $1,624,000 |
| Income Tax Paid Supplemental Data | - | $0 | $1,003,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $-12,500,000 | $0 |
| Net Long Term Debt Issuance | - | $0 | $-12,500,000 | $0 |
| Long Term Debt Payments | - | $0 | $-12,500,000 | $0 |
| Depreciation | - | - | - | $1,676,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-08-19